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Analysis of proteasomal subunit expression reveals Rpt4 as a prognostic 
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Abstract 
Colorectal cancer is a leading cause of cancer related deaths worldwide. Early diagnosis 
and treatment is the key to improving survival rates and as such a need exists to identify 
patients who may benefit from adjuvant chemotherapy. The dysregulation of the 
ubiquitin-proteasome system (UPS) has been implicated in oncogenesis and cancer cell 
survival, and proteasome inhibitors are in clinical use for a number of malignancies 
including multiple myeloma. In this study we examined the protein expression of several 
key components of the ubiquitin-proteasome system in colorectal cancer using 
immunohistochemistry to determine expression levels of ubiquitinylated proteins and the 
proteasomal subunits, 20S core and Rpt4 in a cohort of 228 colon cancer patients.  
Multivariate Cox analysis revealed that neither the intensity of either ubiquitinylated 
proteins or the 20S core were predictive in either Stage II or III colon cancer for disease 
free survival or overall survival. In contrast, in Stage II patients increased Rpt4 staining 
was significantly associated with better disease free survival (Cox proportional hazard 
ratio 0.605; p=0.0217). Our data suggest that Rpt4 is an independent prognostic variable 
for Stage II colorectal cancer and may aid in the decision of which patients undergo 
adjuvant chemotherapy. 
 
 
Introduction 
Colorectal cancer is the third leading cause of cancer – related death in the US with half a 
million deaths worldwide each year 
1
. This is in part due to up to 75% of patients having 
locally advanced disease at presentation and despite advances in surgery and therapeutics, 
up to 40% of patients will experience disease relapse or distant progression 
2
.  To date the 
identification of patients most likely to develop disease recurrence relies mainly on 
clinical and pathological staging strategies; however there is considerable variability in 
survival among similarly staged patients 
3
. For clinicians, the ultimate challenge lies in 
selecting those patients most likely to derive benefit from chemotherapeutics and 
experience minimal side effects. Undoubtedly a need exists to identify novel molecular 
markers which predict patient outcome and identify patients who may benefit from 
adjuvant chemotherapy. Advances in research and technology may now have the 
potential to assist in the integration of cancer biology and patient clinicopathological 
parameters, facilitating an improved clinical decision pathway. Currently surgical 
resection is the mainstay treatment for colorectal cancer patients in the presence and 
absence of 5-fluorouracil based adjuvant chemotherapy, although not all patients treated 
with chemotherapy will derive a benefit from it 
4, 5
.   Indeed, particularly in patients with 
Stage II disease the advantage of adjuvant chemotherapy remains contentious 
6-8
. 
 
The ubiquitin-proteasome system is the major pathway for the degradation of the 
intracellular proteins and as such can modulate a variety of signaling pathways. Proteins 
destined for degradation are tagged with a chain of ubiquitin moieties to a lysine residue 
in the target protein in a series of enzyme catalyzed reactions which ultimately results in 
the targeting of proteins to the proteasome complex 
9
. The proteasome complex itself is a 
large multi-subunit complex composed of a 20S catalytic unit and 19S regulatory 
subunits 
10, 11
. Several lines of evidence have pointed to the dysregulation of the 
ubiquitin-proteasome pathway in cancer where it is thought to be involved in oncogenesis 
and cancer cell survival 
12
. Indeed,  much research has centered on targeting the 
ubiquitin-proteasome system in a number of different malignancies 
13
, with the 
proteasome inhibitor, bortezomib, currently in clinical use as a therapy for multiple 
myeloma 
14
. 
 
Previous studies have demonstrated elevated levels of 19S proteasome subunits in 
ovarian carcinoma tissues 
15
 and higher levels of the 19S proteasomal subunit, Rpt1, were 
observed in breast cancer tissue specimens compared to patient matched normal adjacent 
tissue as controls correlating with increased proteasomal activity 
16
. However, to our 
knowledge no study to date has examined the potential of proteasomal subunits as 
prognostic markers in colorectal cancer.  In this study we examined the 
immunohistochemical expression of several components of the UPS namely the levels of 
ubiquitinylated proteins, the 20S proteasomal catalytic core and the 19S regulatory 
subunit, Rpt4 and their correlation with clinicopathological features and prognosis in a 
large cohort of Stage II and III colorectal tumors. 
 
Materials and Methods 
 
Patients and Tissue Specimens 
Tissue microarrays (TMAs) were constructed from 228 colorectal cancer cases taken 
from a phase III trial of adjuvant 5-flurouracil – based chemotherapy compared to 
postoperative observation alone 
17
. The study group consisted of 228 non-consecutive 
patients with demographic variables including gender and age at surgery recorded. 
Histological stage II and III, tumor grade, TMN stage and presence or absence of 
vascular invasion were included in the analysis and whether the patients were randomised 
to adjuvant chemotherapy with 5-FU or no treatment was noted (Table 1). Time to 
disease progression, including age at recurrence, site of recurrence and time to recurrence 
were also verified. At the time of analysis, a median follow of 6.5 years was available for 
analysis. Full ethical approval was granted for this study. TMAs consisted of paraffin 
embedded colorectal cancer specimens from patients with a positive diagnosis of 
colorectal adenocarcinoma, stage II and III 
18
. Morphologically representative tissue areas 
from tumor specimens and normal adjacent tissue were arrayed on tissue arrays and 
subsequently utilized to determine expression levels of ubiquitinylated proteins, 20S Core 
and Rpt4.  Expression was then correlated to patient demographics, adjuvant treatment 
regimens and histological parameters.  
 
Immunohistochemistry 
Sections 4 µm in thickness were cut from array blocks and floated onto adhesive slides. 
Sections were then baked at 55° C overnight. All staining was carried out on a BondMax 
automated immunostainer from Vision BioSystems. Sections were loaded onto the 
system and the relevant program was started. The BondMax system dewaxed the slides 
and then carried out and antigen retrieval was performed. Sections were stained with 
antibodies against ubiquitinylated proteins (Cell Signaling Technology, MA, USA), the 
20S core (Enzo Life Sciences, Lausen, Switzerland) or Rpt4 (Enzo Life Sciences). 
Optimisation steps were carried out to determine appropriate antibody dilution, which 
were 1:1500 for ubiquitinylated proteins; 1:200 for the 20S core and 1:1000 for Rpt4. 
Following detection using diaminobenzidine the sections were then counterstained lightly 
with haematoxylin, and mounted with coverslips. 
 
Immunohistochemical Evaluation  
Immunostained slides were scored for ubiquitinylated proteins, 20S and Rpt4 using a 
standardised scoring system. Each slide was evaluated using light microscopy with 
respect to intensity. An intensity score was assigned that represents the average intensity 
of the positive cells (0 = no staining; 1 = weak; 2 = moderate; 3 = strong). Slides were 
scored by two independent pathologists (SC and EK) blinded to the clinic-pathological 
data and entered into a database.  In all cases with scoring discrepancies between 
individual pathologists, slides were reviewed and scoring assigned following consensus   
agreement.  As multiple cores for each patient were arrayed, subsequent statistical 
analysis was carried out using median intensity scores. 
 
Statistical Analysis 
Univariate and multivariate analysis was carried out using logistic regression and Cox’s 
proportional hazard model. Univariate analysis of overall and progression-free survival 
was performed by the Kaplan-Meier method and log-rank test and carried out in SPSS for 
Windows 15.0 (SPSS Inc, Chicago, IL). Staining intensity was stratified for Kaplan-
Meier survival plot and log rank analysis according to the following criteria; median 
intensity values of less than 2 were considered weak staining and greater or equal to 2 
were considered strong staining. Variables included in the multivariate analysis included 
gender, age at surgery, stage of colorectal cancer, tumor stage, intensity of staining for 
the individual proteins of interest and whether the patient was randomized to receive 5-
flurouracil chemotherapy. A p-value of less than 0.05 was considered significant. 
 
Results 
Clinicopathological features and patient outcome  
The study was performed on a tissue microarray constructed from surgical resection 
samples of Stage II and Stage III colorectal cancer patients which were collected as part 
of a trial of adjuvant 5-fluorouracil based chemotherapy compared to postoperative 
observation alone 
17
.   The demographics of the patients are shown in Table 1 along with 
the clinicopathological features of tumor site, grade of differentiation and vascular 
invasion (Table 1). As expected, increasing stage was significantly associated with risk of 
distant recurrence and death (Log rank test; p<0.05). The results compare favorably with 
internationally acceptable 5 and 10 year survival rates for Stage II and III colonic 
carcinoma 
19
. There was no statistically significant improvement in overall and disease 
free survival in stage II patients who received chemotherapy compared to those who 
underwent observation (Chi-squared test; χ2(1)=0.415, p> 0.05). Evidence based practice 
advocates the use of adjuvant chemotherapy in stage III CRC, and while no statistically 
significant benefits in either overall or disease free survival were observed in this study, a 
trend towards significance was achieved (Chi-squared test; χ2(1)=3.326, p = 0.068), 
which is likely attributable to the smaller number of Stage III patients involved in this 
study. 
 
Expression of ubiquitin-proteasome system proteins in tumor tissue and correlation 
with clinical outcome 
The tissue microarrays (TMAs) were prepared and representative sections of tumor tissue 
stained with each of the antibodies are shown in Figure 1.  The TMAs were scored for the 
expression of ubiquitinylated proteins as well as the proteasomal subunits, 20S core and 
Rpt4 as described in the materials and methods section. Survival analyzes were 
performed with 6.5 year median follow up clinical data available. Kaplan Meier survival 
curves were generated to determine if a significant relationship existed between the 
expression levels of ubiquitinylated proteins, the 20S core subunit or Rpt4 expression 
scores and both disease free and overall survival in our cohort of Stage II and III patients.  
 
Ubiquitinylated Proteins: The expression of ubiquitinylated proteins was detected in 
96% of tumor specimens and localized to both the cytoplasm and nucleus of cells. The 
intensity of ubiquitinylated proteins staining was not found to be a predictive of time to 
disease free survival in stage II colon cancer, however, a trend towards significance exists 
(Hazard Ratio  (HR) =0.658; p=0.0605). Analysis of stage III disease patients revealed 
that levels of ubiquitinylated proteins were not predictive of predict disease recurrence 
(Table 2; Figure 2A). Overall survival analysis of ubiquitinylated protein expression 
showed that it was not a predictor of death in either stage II or III patients (Table 3; 
Figure 3A).  
 
 
 
20S proteasome core: Next we examined the expression of the 20S proteasome core. 
Expression was detected in 96% of tumor specimens and was consistent with the known 
cytoplasmic and nuclear localization of proteasomes 
20
. Univariate and multivariate 
analysis of our cohort of stage II and III patients indicated that the expression of the 20S 
proteasome core was not predictive of those patients more likely to experience disease 
recurrence (Table 2; Figure 2B). Likewise, in the same cohort of stage II and III patients, 
20S core staining did not predict those patients who were likely to die from their disease 
(Table 3; Figure 3B).  
 
Rpt4 subunit: Finally we examined the relationship between the expression levels of the 
19S proteasome subunit, of Rpt4, and disease free and overall survival. In Stage II 
patients, increased expression of Rpt4 significantly predicted patients who were less 
likely to experience disease recurrence. This effect was also evident when analyzed by 
Kaplan Meier analysis (Figure 2C). There was no similar correlation between Rpt4 
expression and disease free survival in Stage III patients (Table 2; Figure 2C).  
Interestingly, although Log Rank analysis revealed that increased Rpt4 intensity in Stage 
II patients also predicted those who were more likely to have survived (OR = 0.648, 
p=0.0467) Rpt4 expression was not predictive of time to death in univariate analysis or 
multivariate analysis (Table 3; Figure 3C). There was no significant association between 
Rpt4 intensity and overall survival in Stage III patients (Table 3).  
Discussion 
Discrepancies in survival of patients with node negative colorectal carcinoma are most 
often attributable to the presence of micro-metastases that are too small and thus 
undetectable at the time of staging by conventional pathological staging mechanisms 
21
, 
leading to heterogeneity in survival among patients who have comparable disease stages. 
Identification of prognostic biomarkers would select out high risk patients who are likely 
to experience disease recurrence and would theoretically benefit from further adjuvant 
therapies, while avoiding unnecessary toxicity to those who will not benefit, remains the 
rationale for targeted patient treatment modalities.   
 
With this in mind we employed tissue microarray technology to assay the 
immunohistochemical expression of a number of components of the ubiquitin-
proteasome pathway in a large cohort of node negative stage II and node positive stage 
III patients. Immunohistochemical staining with an antibody which recognized mono- 
and poly-ubiquitinylated proteins and subsequent correlation with clinico-pathological 
data revealed that the intensity of staining of ubiquitinylated proteins was not a 
prognostic marker for disease free survival and time to death in either Stage II or III 
colorectal cancer patients. Similar results were evident when the tissue microarray was 
stained with an antibody recognizing the 20S core. In contrast, increased Rpt4 expression 
was found to be a significant positive prognostic marker for disease free survival and 
time to death in Stage II patients but not in Stage III patients. 
 
The ubiquitin-proteasome pathway plays a major role in the facilitating protein 
degradation and in such a manner modulates a number of cellular signaling pathways 
including those involved in cell cycle regulation and apoptosis 
22
, both of which are 
affected in colon cancer. The 19S regulatory subunit of the proteasome, of which Rpt4 is 
an integral component, plays a role in substrate unfolding prior to entering the catalytic 
core chamber 
23, 24
 and represents a potential target for development of novel 
chemotherapeutic treatment modalities. Currently the benefit of adjuvant chemotherapy 
to patients with Stage II disease remains controversial 
6-8
. We have determined that 
decreased Rpt4 expression is significantly associated with decreased time to disease 
progression in Stage II patients. This finding may support the potential of Rpt4 as a 
prognostic biomarker in identifying patients who are likely to experience disease 
recurrence and thus would benefit from further adjuvant therapies and those who are less 
likely to develop recurrence and therefore would not gain any survival advantage from 
additional treatments.  Furthermore, a recent study has linked a member of the ubiquitin-
like modifier family, Ubiquitin D (UBD), as a potential prognostic marker in stage II-III 
colorectal cancer 
25
. In future studies it may be interesting to combine Rpt4 expression 
alongside UBD to enhance the identification of patients who may benefit from adjuvant 
chemotherapy. In conclusion, we have identified a novel finding that increased 
expression of the 19S proteasomal subunit Rpt4 correlated with increased disease free 
and overall survival in a cohort of Stage II colon cancer patients. Such observations may 
be of future use for clinicians in identifying patients who will benefit from adjuvant 
chemotherapy. 
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Table 1: Clinicopathological features of colon cancer patient cohort. 
 
Table 2: Effect of individual marker scores on disease free survival as assessed using 
Cox regression proportional analysis.  
 
Table 3: Effect of individual marker scores on overall survival as assessed using Cox 
regression proportional analysis.  
 
Figure 1: Representative images of immunohistochemical expression of ubiquitinylated 
proteins, the 20 S core and Rpt4 expression in tumor colonic tissue specimens. (A) 
Ubiquitinylated proteins (B) 20S core (C) Rpt4.  Sections were scored for intensity 
staining.  
 
Figure 2: Kaplan-Meier survival curve of disease free survival for ubiquitinylated 
proteins (A),  20S core (B) and Rpt4 (C).  Intensity staining scores of 0-1 were classified 
as weak staining and scores of 2-3 classified as strong staining. 
 
Figure 3: Kaplan-Meier survival curve of overall survival for ubiquitinylated proteins 
(A), 20S core (B) and Rpt4 (C). Intensity staining scores of 0-1 were classified as weak 
staining and scores of 2-3 classified as strong staining. 
 
TABLE 1: CLINICOPATHOLOGIC DETAILS OF COLORECTAL CANCER      
PATIENT COHORT (N=228) 
 Chemotherapy No Treatment 
Age (years)   
     Mean 64.58 63.69 
     Median 66 65 
     Range 45.75 - 80.96 35.01 - 79.63 
Gender   
     Male 64 (56.6%) 71 (61.7%) 
     Female 49 (43.4%) 44 (38.3%) 
Stage   
     II 69 (61.1%) 76 (66.1%) 
     III 44 (38.9%) 39 (33.9%) 
Tumour Site   
     Right Colon 46 (40.7%) 41 (35.7%) 
     Left Colon 42 (37.2%) 48 (41.7%) 
     Synchronous 3 (2.7%) 0 (0%) 
     Rectum 22 (19.5%) 26 (22.6%) 
Grade of differentiation   
     Grade 1 9 (8%) 10 (8.7%) 
     Grade 2 86 (76.1%) 86 (74.8%) 
     Grade 3 14 (12.4%) 13 (11.3%) 
     Not specified 4 (3.5%) 6 (5.2%) 
Vascular invasion   
     No 58 (51.3%) 62 (53.9%) 
     Yes 27 (23.9%) 23 (20%) 
      Not specified 28 (24.8%) 30 (26.1%) 
 
Marker 
Disease Free Survival 
Stage II Stage III 
Univariate Multivariate Univariate Multivariate 
HR                         
(95% CI) 
p-
value 
HR                   
(95% CI) 
p-
value 
HR                        
(95% CI) 
p-
value 
HR                 
(95% CI) 
p-value 
Ubiquitinylated  
proteins 
0.658             
(0.425 - 1.019) 
0.0605 
0.676           
(0.435 - 1.050)  
0.0817 
1.192                 
(0.885 – 1.587)  
0.2302 
1.1117               
(0.824 – 1.514)  
0.4758 
20S 
proteasomal  
core 
0.806             
(0.566 - 1.147)  
0.2307 
0.791                
(0.554 - 1.131)  
0.1991 
1.150                
(0.882 - 1.500) 
0.3023 
1.136                
(0.855 - 1.509)  
0.3795 
RPT4 
proteasomal 
subunit 
0.605                   
(0.394 – 0.929)  
0.0217 
0.613                
(0.398 – 0.945) 
0.0265 
1.097              
(0.825 - 1.459) 
0.5233 
1.026               
(0.758 - 1.390) 
0.8665 
 
Table 2 
Marker 
Overall  Survival 
Stage II Stage III 
Univariate Multivariate Univariate Multivariate 
HR                         
(95% CI) 
p-
value 
HR                   
(95% CI) 
p-
value 
HR                        
(95% CI) 
p-
value 
HR                 
(95% CI) 
p-value 
Ubiquitinylated  
proteins 
0.831             
(0.596 - 1.158) 
0.2746 
0.798           
(0.565 - 1.127)  
0.2005 
1.356                 
(0.863 - 2.130)  
0.1869 
1.264               
(0.572 - 2.796)  
0.5624 
20S 
proteasomal  
core 
0.841              
(0.583 - 1.213)  
0.3529 
0.913                
(0.639 - 1.306)  
0.619 
1.072                
(0.832 - 1.380) 
0.593 
1.033                
(0.785 - 1.359)  
0.8154 
RPT4 
proteasomal 
subunit 
0.841                   
(0.616 - 1.148)  
0.2757 
0.842                
(0.606 - 1.170) 
0.3059 
1.018              
(0.775 - 1.337) 
0.8996 
0.958               
(0.719 - 1.278) 
0.7724 
 
Table 3 



